Immunocytokines Market Report 2025

The immunocytokines market size has grown strongly in recent years. It will grow from $3.25 billion in 2024 to $3.56 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the rising prevalence of cancer cases, an increased focus on targeted cancer therapies, growing investments in biologics research, the rising clinical success of immunotherapy trials, and heightened awareness of personalized medicine.

The immunocytokines market size is expected to see strong growth in the next few years. It will grow to $5.0 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth during the forecast period can be attributed to the rising demand for precision oncology treatments, an expanding pipeline of next-generation immunocytokines, growing interest in rare and orphan disease therapies, increased penetration in emerging markets, and greater adoption of outpatient biologic therapies. Major trends expected in the forecast period include advancements in fusion protein engineering, the use of advanced biomanufacturing technologies, innovations in targeted delivery systems, integration of artificial intelligence in clinical development, and the development of tumor-specific cytokine payloads.

The rising prevalence of autoimmune diseases is expected to drive growth in the immunocytokines market. Autoimmune diseases occur when the body’s immune system mistakenly attacks healthy cells and tissues. This increase is largely linked to heightened exposure to environmental pollutants, which can disrupt immune function and trigger immune attacks. Immunocytokines address autoimmune conditions by combining targeted immune modulation with precision delivery, minimizing systemic side effects while improving treatment efficacy. For example, a 2022 survey by Versorgungsatlas.de in Germany reported that out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, corresponding to a prevalence rate of 8.61%.

Companies in the immunocytokines market are developing innovative antibody-cytokine fusion proteins to deliver cytokines specifically to diseased tissues, enhancing therapeutic efficacy and reducing systemic toxicity. In July 2023, SunHo BioPharmaceutical Co. Ltd., a China-based company, launched IBB0979 (B7H3-IL-10 immunocytokine) for advanced or metastatic solid tumors. This fusion protein combines the tumor-targeting ability of the B7H3 antibody with the anti-inflammatory and immune-modulating effects of interleukin-10 (IL-10), modifying the tumor microenvironment to reduce inflammation and boost anti-tumor immune responses. IBB0979 is currently in Phase I/II clinical trials.

In September 2022, F. Hoffmann-La Roche AG acquired Good Therapeutics Inc. for $250 million to strengthen its oncology pipeline. Good Therapeutics, a US-based biotech company, specializes in IL-2 immunocytokines that deliver targeted cancer therapies, enabling Roche to expand its portfolio of precision cancer immunotherapies with conditionally active, tissue-specific treatments.

Major players in the immunocytokines market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Innovent Biologics Inc., Xencor Inc., Nektar Therapeutics, PDS Biotechnology Corporation, Synthekine Inc., Philogen S.p.A, Werewolf Therapeutics Inc., SOTIO Biotech, Xilio Therapeutics Inc., Dragonfly Therapeutics Inc., Apeiron Biologics AG, Kanaph Therapeutics Inc, Cytimmune Sciences Inc., Cytune Pharma S.A.S.

North America was the largest region in the immunocytokines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunocytokines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the immunocytokines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Immunocytokines are engineered fusion proteins that combine cytokines with antibodies or antibody fragments. Their primary function is to deliver immune-stimulating cytokines directly to target cells or tissues, enhancing the immune response against diseases such as cancer while reducing systemic side effects. This targeted approach improves the therapeutic efficacy of cytokines while minimizing systemic toxicity.

The primary types of immunocytokines include interleukins, interferons, tumor necrosis factors, and others. Interleukins are a group of cytokines, or signaling proteins, mainly produced by white blood cells, and they play a key role in regulating immune responses, inflammation, and blood cell development. Their mechanisms of action include functioning as antagonists, agonists, or immune modulators, and they are applied in treatments for cancer, autoimmune diseases, infectious diseases, and more, serving end-users such as hospitals, research institutes, specialty clinics, and other healthcare settings.

The immunocytokines market research report is one of a series of new reports that provides immunocytokines market statistics, including immunocytokines industry global market size, regional shares, competitors with an immunocytokines market share, detailed immunocytokines market segments, market trends and opportunities, and any further data you may need to thrive in the immunocytokines industry. This immunocytokines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immunocytokines market consists of sales of body-cytokine fusion proteins, IL-2-based immunocytokines, and IL-12-based immunocytokines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.